Latest Tax News

Orion Equities (ASX:OEQ) returned to profitability in FY26 with a $204,000 net profit, buoyed by a $400,000 uplift in investment property value. Despite a 7% dip in total revenue, net tangible asset backing per share edged up to $0.43, while no dividend was declared.

FlexiRoam Limited (ASX:FRX) reported a statutory net profit after tax of $0.7 million for FY26, reversing a $2.0 million loss in FY25, driven by a pivot to higher-quality recurring revenue and operational discipline.

Castile Resources reveals a robust 2026 Scoping Study for its Rover 1 IOCG Project, projecting an 11-year underground mine life with five valuable metals driving strong economics and a staged development strategy.

OMG Group posted a 48% revenue increase to $6.13 million in FY26, achieving its highest-ever gross margin of 41% while expanding distribution into New Zealand and Southeast Asia.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Orcoda Limited reported a 26% reduction in net loss and a 23% rise in Annual Recurring Revenue, boosted by a new $8 million per annum multi-year contract with Wagner Corporation, setting the stage for SaaS expansion in FY27.

Waterco Limited delivered a robust turnaround in FY26 with net profit after tax soaring 61.6% to $15.5 million on modest revenue growth. The company expanded its Swimart franchise, advanced manufacturing insourcing, and boosted dividends to 20 cents per share fully franked.

Jatcorp Limited's FY26 results show a 23% revenue increase to $38.9 million but a 41% larger loss attributable to owners. The company faces a material uncertainty over going concern despite improved statutory NPAT.

Staude Capital Global Value Fund Limited posted a 47% drop in net profit after tax for FY2026 amid a 39% revenue decline, while adjusted pre-tax NTA rose 7%. The company declared a fully franked final dividend of 3.3 cents per share and completed a $18.2 million share purchase plan last year.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.

Moonlight Resources Ltd (ASX: ML8) completed its first year as a listed entity, rapidly expanding its gold and copper exploration at the Clermont Project in Queensland. The company reported a net loss of $1.98 million for FY2026, reflecting active exploration and corporate growth following its December 2025 IPO.

Boresight Ltd (ASX: BST) recorded a 46% increase in revenue to $6.38 million for FY26, driven by global sales expansion and strategic investments including an $8 million IPO. Despite this growth, the company posted a $6.66 million net loss, largely due to increased operational expenses and significant share-based payments.